Union Bancaire Privee UBP SA Sells 2,687 Shares of Zoetis Inc. $ZTS

Key Points

• Union Bancaire Privee UBP SA reduced its stake in Zoetis Inc. by 65.0%, selling 2,687 shares in the second quarter, leaving it with 1,450 shares valued at $216,000.
• Recent earnings showed Zoetis reported $1.76 earnings per share, surpassing analysts' expectations of $1.62, with revenues of $2.46 billion.
• Analysts have mixed views on Zoetis, with ratings ranging from "buy" to "hold," and an average price target of $200.88.

Union Bancaire Privee UBP SA lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 65.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,450 shares of the company's stock after selling 2,687 shares during the quarter. Union Bancaire Privee UBP SA's holdings in Zoetis were worth $216,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nova Wealth Management Inc. bought a new position in shares of Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new position in Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank bought a new position in Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, ORG Partners LLC raised its position in Zoetis by 56.8% in the 2nd quarter. ORG Partners LLC now owns 232 shares of the company's stock valued at $37,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 0.4%

ZTS stock opened at $146.87 on Thursday. The company has a market cap of $65.09 billion, a P/E ratio of 25.28, a PEG ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The business has a fifty day moving average of $150.02 and a 200-day moving average of $155.39.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research analyst reports. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Finally, Argus reiterated a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.